MIS Sacroiliac Joint Fusion Market Size, Share, & Trends Analysis - Global - 2025-2031
Description
Global MIS SI Joint Fusion Market Report, 2025 Edition
Executive Summary
The global minimally invasive sacroiliac (MIS SI) joint fusion market was valued at approximately $330 million in 2024. It is projected to grow at a compound annual growth rate (CAGR) of 8.8 percent to reach nearly $595 million by 2031.
This report covers unit sales, average selling prices (ASPs), market values, growth rates, and company shares, while analyzing market drivers, limiters, mergers and acquisitions (M&A), and technological developments. Historical data are provided from 2021 to 2024, with forecasts through 2031.
MIS SI joint fusion procedures stabilize the sacroiliac joint through small incisions, offering patients faster recovery and lower complication risks compared with open fusion techniques. These devices are increasingly adopted as the clinical recognition of sacroiliac joint dysfunction (SIJD) as a significant cause of lower back pain continues to rise.
With growing awareness among physicians and patients, minimally invasive sacroiliac joint fusion has become a key treatment option for individuals whose pain originates from the sacroiliac joint rather than the lumbar spine. The market’s expansion reflects the convergence of rising diagnosis rates, procedural advantages, and advancements in implant design and instrumentation.
Market Overview
The sacroiliac joint (SI joint) connects the sacrum at the base of the spine to the iliac bones of the pelvis. Dysfunction or instability of this joint can cause chronic pain that mimics symptoms of lumbar spine conditions. Historically underdiagnosed, SI joint dysfunction has gained recognition in recent years as studies suggest it may account for up to one-third of all lower back pain cases.
Minimally invasive sacroiliac joint fusion involves stabilizing the joint using implants or screws inserted through small incisions, typically guided by fluoroscopy or navigation. Compared to open fusion procedures, MIS techniques reduce operative time, minimize blood loss, and shorten hospital stays. Patients benefit from less postoperative pain and faster return to daily activities.
Market growth is driven by several factors, including the aging population, increased surgical awareness, and an expanding number of surgeons trained in MIS techniques. The procedure is gaining traction not only in North America but also across Europe and Asia-Pacific, as reimbursement coverage improves and device innovation accelerates.
Despite relatively higher implant costs compared with non-surgical alternatives, hospitals and ambulatory surgical centers are adopting MIS SI fusion due to its clear clinical and economic benefits—particularly reduced readmission rates and improved patient satisfaction scores.
Over the forecast period, continued advancements in implant materials, improved diagnosis accuracy, and expanded training will support sustained double-digit growth in many regions.
Market Drivers
Adjacent Segment Disease
The increasing number of lumbar fusion procedures worldwide is contributing to growth in the MIS SI joint fusion market. After spinal fusion, many patients develop adjacent segment degeneration (ASD), where increased stress on nearby spinal segments leads to deterioration. Studies indicate that degeneration of the sacroiliac joint plays a key role in many ASD cases.
As more lumbar fusions are performed each year, the number of patients requiring sacroiliac stabilization is also increasing. This growing pool of potential candidates fuels steady demand for MIS SI joint fusion devices.
Increased Awareness of SI Dysfunction
For many years, the SI joint was not recognized as a major source of chronic back pain. However, recent clinical research has shown that the SI joint contributes to 30 to 35 percent of lower back pain cases. This growing awareness has led to improved diagnostic protocols and more accurate identification of sacroiliac dysfunction.
As both physicians and patients become more informed, referrals for SI joint fusion have increased. Expanding education initiatives, peer-reviewed evidence, and physician training programs are driving more consistent diagnosis and treatment planning. Greater recognition of the SI joint as a true pain generator is expected to remain one of the strongest growth drivers for this market.
Minimally Invasive Surgery Preference
Patients continue to favor minimally invasive procedures over traditional open approaches whenever possible. MIS SI joint fusion offers multiple advantages, including reduced tissue disruption, fewer complications, shorter hospital stays, and quicker recovery times.
For healthcare providers, these benefits translate into greater operational efficiency and cost savings. MIS procedures can often be performed on an outpatient basis, helping reduce hospital resource utilization. Positive clinical outcomes and strong patient satisfaction reinforce the trend toward minimally invasive SI fusion and sustain long-term market growth.
Market Limiters
Absence of Long-Term Clinical Data
Although early- and mid-term results for MIS SI joint fusion are promising, there remains a lack of long-term clinical data validating the durability of these implants. Many spine and orthopedic surgeons rely heavily on multi-year follow-up studies when deciding which devices to adopt.
This limited long-term evidence delays broader clinical acceptance and slows updates to insurance reimbursement policies. Until a more substantial body of longitudinal research is available, some physicians will continue to take a cautious approach to adopting MIS SI fusion technology.
Diagnosis of SI Dysfunction
Despite improvements in awareness, misdiagnosis remains a challenge. Because symptoms of SI joint dysfunction often resemble those of lumbar spine disorders, many patients continue to be treated for the wrong condition.
This diagnostic ambiguity can lead to unnecessary lumbar fusions while delaying proper treatment for SI joint pain. Developing standardized diagnostic criteria and advanced imaging or functional tests is critical to improving the accuracy of diagnosis and expanding the eligible patient population for MIS SI fusion procedures.
Preference for Non-Surgical Treatments
Many physicians and patients still prefer non-surgical management options, such as physical therapy, injections, and radiofrequency ablation. These conservative treatments are often tried before surgical fusion is considered.
While these alternatives limit immediate procedural growth, they also serve as part of the treatment continuum, eventually funneling patients toward surgical intervention when non-surgical methods fail. As diagnosis rates and confidence in MIS procedures increase, conversion from conservative management to surgery is expected to rise gradually.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
Qualitative Coverage
Market growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles, product portfolios, FDA approvals and recalls, disruptive technologies, and disease overviews.
Time Frame
Historical data: 2021–2024
Base year: 2024
Forecast period: 2025–2031
Data Sources
Primary interviews with surgeons and hospital procurement officers, government and regulatory data, hospital usage statistics, import and export data, and iData Research’s internal MedTech database.
Markets Covered and Segmentation
Global Minimally Invasive Sacroiliac (MIS SI) Joint Fusion Market – Further Segmented Into:
Market analysis by units sold, ASPs, and total market value.
Competitive Analysis
SI-BONE was the global leader in the MIS SI joint fusion market in 2024, holding approximately half of the total market share. The company pioneered this space with its iFuse Implant System® (iFuse®) and maintains dominance across all major regions, including North America, Western Europe, and the Rest of the World. Its strong clinical evidence, surgeon education programs, and broad reimbursement coverage solidify its leadership position.
Medtronic ranked second globally, supported by its ANCHOR FS™ system. The company leverages its global distribution network and reputation for high-quality spinal solutions to expand its market presence. Medtronic ranked second in Western Europe and the Rest of the World, and maintained a significant presence in North America.
Globus Medical/NuVasive was the third-leading competitor in 2024, with its ZYFUSE® system. Following their merger in 2023, the combined company has strengthened its product development and commercialization capabilities. Globus Medical/NuVasive ranked third in Western Europe and the Rest of the World, with growing recognition among spine surgeons for its innovative implant design.
Overall, the market is moderately concentrated, with the top three players accounting for the majority of global revenue. Their continued investment in education, research, and product differentiation will sustain their advantage, though smaller regional manufacturers are emerging with cost-effective alternatives.
Technology and Practice Trends
3D imaging and navigation technologies are improving accuracy in implant placement and reducing radiation exposure for surgeons and patients.
Titanium and porous-coated implants enhance osseointegration and long-term stability, supporting improved clinical outcomes.
Modular and screw-based implant systems provide surgeons with flexibility in addressing a variety of anatomical challenges.
Outpatient SI fusion procedures are increasing, especially in North America, due to cost savings and improved recovery times.
Digital preoperative planning tools are helping surgeons simulate procedures and optimize implant selection.
Clinical studies and registries continue to expand, building the long-term evidence base necessary for broader reimbursement and adoption.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global MIS SI joint fusion market?
How does rising awareness of SI joint dysfunction influence procedural demand?
Which regions and manufacturers are positioned for the highest growth through 2031?
How do reimbursement and clinical data availability affect market penetration across regions?
What emerging technologies are driving innovation in implant design and surgical technique?
How do diagnostic challenges and patient selection influence procedure volumes?
What factors will shape long-term competition between MIS fusion and non-surgical alternatives?
The Global MIS SI Joint Fusion Market Report from iData Research answers these questions with detailed device-level data, company share analysis, and procedure-based forecasts. Use it to identify growth opportunities, refine marketing strategies, and plan product development within the rapidly expanding field of minimally invasive spinal surgery.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Executive Summary
The global minimally invasive sacroiliac (MIS SI) joint fusion market was valued at approximately $330 million in 2024. It is projected to grow at a compound annual growth rate (CAGR) of 8.8 percent to reach nearly $595 million by 2031.
This report covers unit sales, average selling prices (ASPs), market values, growth rates, and company shares, while analyzing market drivers, limiters, mergers and acquisitions (M&A), and technological developments. Historical data are provided from 2021 to 2024, with forecasts through 2031.
MIS SI joint fusion procedures stabilize the sacroiliac joint through small incisions, offering patients faster recovery and lower complication risks compared with open fusion techniques. These devices are increasingly adopted as the clinical recognition of sacroiliac joint dysfunction (SIJD) as a significant cause of lower back pain continues to rise.
With growing awareness among physicians and patients, minimally invasive sacroiliac joint fusion has become a key treatment option for individuals whose pain originates from the sacroiliac joint rather than the lumbar spine. The market’s expansion reflects the convergence of rising diagnosis rates, procedural advantages, and advancements in implant design and instrumentation.
Market Overview
The sacroiliac joint (SI joint) connects the sacrum at the base of the spine to the iliac bones of the pelvis. Dysfunction or instability of this joint can cause chronic pain that mimics symptoms of lumbar spine conditions. Historically underdiagnosed, SI joint dysfunction has gained recognition in recent years as studies suggest it may account for up to one-third of all lower back pain cases.
Minimally invasive sacroiliac joint fusion involves stabilizing the joint using implants or screws inserted through small incisions, typically guided by fluoroscopy or navigation. Compared to open fusion procedures, MIS techniques reduce operative time, minimize blood loss, and shorten hospital stays. Patients benefit from less postoperative pain and faster return to daily activities.
Market growth is driven by several factors, including the aging population, increased surgical awareness, and an expanding number of surgeons trained in MIS techniques. The procedure is gaining traction not only in North America but also across Europe and Asia-Pacific, as reimbursement coverage improves and device innovation accelerates.
Despite relatively higher implant costs compared with non-surgical alternatives, hospitals and ambulatory surgical centers are adopting MIS SI fusion due to its clear clinical and economic benefits—particularly reduced readmission rates and improved patient satisfaction scores.
Over the forecast period, continued advancements in implant materials, improved diagnosis accuracy, and expanded training will support sustained double-digit growth in many regions.
Market Drivers
Adjacent Segment Disease
The increasing number of lumbar fusion procedures worldwide is contributing to growth in the MIS SI joint fusion market. After spinal fusion, many patients develop adjacent segment degeneration (ASD), where increased stress on nearby spinal segments leads to deterioration. Studies indicate that degeneration of the sacroiliac joint plays a key role in many ASD cases.
As more lumbar fusions are performed each year, the number of patients requiring sacroiliac stabilization is also increasing. This growing pool of potential candidates fuels steady demand for MIS SI joint fusion devices.
Increased Awareness of SI Dysfunction
For many years, the SI joint was not recognized as a major source of chronic back pain. However, recent clinical research has shown that the SI joint contributes to 30 to 35 percent of lower back pain cases. This growing awareness has led to improved diagnostic protocols and more accurate identification of sacroiliac dysfunction.
As both physicians and patients become more informed, referrals for SI joint fusion have increased. Expanding education initiatives, peer-reviewed evidence, and physician training programs are driving more consistent diagnosis and treatment planning. Greater recognition of the SI joint as a true pain generator is expected to remain one of the strongest growth drivers for this market.
Minimally Invasive Surgery Preference
Patients continue to favor minimally invasive procedures over traditional open approaches whenever possible. MIS SI joint fusion offers multiple advantages, including reduced tissue disruption, fewer complications, shorter hospital stays, and quicker recovery times.
For healthcare providers, these benefits translate into greater operational efficiency and cost savings. MIS procedures can often be performed on an outpatient basis, helping reduce hospital resource utilization. Positive clinical outcomes and strong patient satisfaction reinforce the trend toward minimally invasive SI fusion and sustain long-term market growth.
Market Limiters
Absence of Long-Term Clinical Data
Although early- and mid-term results for MIS SI joint fusion are promising, there remains a lack of long-term clinical data validating the durability of these implants. Many spine and orthopedic surgeons rely heavily on multi-year follow-up studies when deciding which devices to adopt.
This limited long-term evidence delays broader clinical acceptance and slows updates to insurance reimbursement policies. Until a more substantial body of longitudinal research is available, some physicians will continue to take a cautious approach to adopting MIS SI fusion technology.
Diagnosis of SI Dysfunction
Despite improvements in awareness, misdiagnosis remains a challenge. Because symptoms of SI joint dysfunction often resemble those of lumbar spine disorders, many patients continue to be treated for the wrong condition.
This diagnostic ambiguity can lead to unnecessary lumbar fusions while delaying proper treatment for SI joint pain. Developing standardized diagnostic criteria and advanced imaging or functional tests is critical to improving the accuracy of diagnosis and expanding the eligible patient population for MIS SI fusion procedures.
Preference for Non-Surgical Treatments
Many physicians and patients still prefer non-surgical management options, such as physical therapy, injections, and radiofrequency ablation. These conservative treatments are often tried before surgical fusion is considered.
While these alternatives limit immediate procedural growth, they also serve as part of the treatment continuum, eventually funneling patients toward surgical intervention when non-surgical methods fail. As diagnosis rates and confidence in MIS procedures increase, conversion from conservative management to surgery is expected to rise gradually.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
Qualitative Coverage
Market growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles, product portfolios, FDA approvals and recalls, disruptive technologies, and disease overviews.
Time Frame
Historical data: 2021–2024
Base year: 2024
Forecast period: 2025–2031
Data Sources
Primary interviews with surgeons and hospital procurement officers, government and regulatory data, hospital usage statistics, import and export data, and iData Research’s internal MedTech database.
Markets Covered and Segmentation
Global Minimally Invasive Sacroiliac (MIS SI) Joint Fusion Market – Further Segmented Into:
Market analysis by units sold, ASPs, and total market value.
Competitive Analysis
SI-BONE was the global leader in the MIS SI joint fusion market in 2024, holding approximately half of the total market share. The company pioneered this space with its iFuse Implant System® (iFuse®) and maintains dominance across all major regions, including North America, Western Europe, and the Rest of the World. Its strong clinical evidence, surgeon education programs, and broad reimbursement coverage solidify its leadership position.
Medtronic ranked second globally, supported by its ANCHOR FS™ system. The company leverages its global distribution network and reputation for high-quality spinal solutions to expand its market presence. Medtronic ranked second in Western Europe and the Rest of the World, and maintained a significant presence in North America.
Globus Medical/NuVasive was the third-leading competitor in 2024, with its ZYFUSE® system. Following their merger in 2023, the combined company has strengthened its product development and commercialization capabilities. Globus Medical/NuVasive ranked third in Western Europe and the Rest of the World, with growing recognition among spine surgeons for its innovative implant design.
Overall, the market is moderately concentrated, with the top three players accounting for the majority of global revenue. Their continued investment in education, research, and product differentiation will sustain their advantage, though smaller regional manufacturers are emerging with cost-effective alternatives.
Technology and Practice Trends
3D imaging and navigation technologies are improving accuracy in implant placement and reducing radiation exposure for surgeons and patients.
Titanium and porous-coated implants enhance osseointegration and long-term stability, supporting improved clinical outcomes.
Modular and screw-based implant systems provide surgeons with flexibility in addressing a variety of anatomical challenges.
Outpatient SI fusion procedures are increasing, especially in North America, due to cost savings and improved recovery times.
Digital preoperative planning tools are helping surgeons simulate procedures and optimize implant selection.
Clinical studies and registries continue to expand, building the long-term evidence base necessary for broader reimbursement and adoption.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global MIS SI joint fusion market?
How does rising awareness of SI joint dysfunction influence procedural demand?
Which regions and manufacturers are positioned for the highest growth through 2031?
How do reimbursement and clinical data availability affect market penetration across regions?
What emerging technologies are driving innovation in implant design and surgical technique?
How do diagnostic challenges and patient selection influence procedure volumes?
What factors will shape long-term competition between MIS fusion and non-surgical alternatives?
The Global MIS SI Joint Fusion Market Report from iData Research answers these questions with detailed device-level data, company share analysis, and procedure-based forecasts. Use it to identify growth opportunities, refine marketing strategies, and plan product development within the rapidly expanding field of minimally invasive spinal surgery.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Table of Contents
51 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
